Microdosing in early lead discovery

Bioanalysis

Volumn 2, Issue 3, 2010, Pages 421-428

  Jekunen, A P ^a   Pauwels, E K J ^b   Kairemo, K J A ^c,d  

^a Central Hospital in Kokkola   (Finland)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF HELSINKI   (Finland)

^d Docrates Oncology Clinic   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ACCELERATOR MASS SPECTROMETRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DECISION MAKING; DRUG MICRODOSE; DRUG RESEARCH; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MASS SPECTROMETRY; MEDICAL ETHICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHARMACODYNAMICS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEADY STATE; TOXICOGENETICS; TOXICOKINETICS; ANIMAL; DRUG DEVELOPMENT; ETHICS; GENETICS; GOVERNMENT REGULATION; LEGAL ASPECT; METHODOLOGY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC);

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG DISCOVERY; GENETICS; GOVERNMENT REGULATION; HUMANS; PHARMACOKINETICS;

EID: 79952458687     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.189     Document Type: Review

References (22)

1. Graul AI. Promoting, improving and accelerating the drug development and approval processes. Drug News Perspect. 22(1), 30-38 (2009).
2. Doroshow JH, Parchment RE. Oncologic Phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clin. Cancer Res. 14(12), 3658-3662 (2008).
3. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J. Clin. Oncol. 25 (2), 209-216 (2007). (Pubitemid 350003036)
4. Adams CP, Branther W. Estimating the cost of new drug development: is it really 802 million? Health Aff. 25, 420-428 (2006). (Pubitemid 43529550)
5. Sparreboom A. Unexplored pharmacokinetic opportunities with microdosing in oncology. Clin. Cancer Res. 13(14), 4033-4034 (2007). (Pubitemid 47105961)
6. Pauwels EK, Bergstrom K, Mariani G, Kairemo K. Microdosing, imaging biomarkers and SPECT: a multi-sided tripod to accelerate drug development. Curr. Pharm. Des. 15(9), 928-934 (2009).
7. LoRusso PM. Phase 0 clinical trials: an answer to drug development stagnation? J. Clin. Oncol. 27(16), 2586-2588 (2009).
8. Garner RC, Lappin G. The Phase 0 microdosing concept. Br. J. Clin. Pharmacol. 61(4), 367-370 (2006).
9. Kummar S, Kinders R, Rubinstein L. Compressing drug development timelines in oncology using Phase 0 trials. Nat. Rev. Cancer 7(2), 131-139 (2007). (Pubitemid 46160988)
10. Boddy AV, Sludden J, Griffin MJ et al. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin. Cancer Res. 13(14), 4164-4169 (2007). (Pubitemid 47105979)
11. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2(7), 566-580 (2003). (Pubitemid 37361748)
12. Bauer M, Wagner CC, Langer O. Microdosing studies in humans: the role of positron emission tomography. Drugs R D 9(2), 73-81 (2008). (Pubitemid 351311221)
13. Deeken J, Figg WD, Bates SE. Toward individualize treatment: prediction of anticancer drug disposition and toxicity with pharmacokinetics. Anticancer Drugs 18, 111-126 (2007). (Pubitemid 44967422)
14. Muller PY, Brennan FR. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin. Pharmacol. Ther. 85(3), 247-258 (2009).
15. Gutierrez M Collyar D. Patient perspectives on Phase 0 clinical trials. Clin. Cancer Res. 14, 3689-3691 (2008).
16. Abdoler E, Taylor H, Wendler D. The ethics of Phase 0 oncology trials. Clin. Cancer Res. 14, 3692-3697 (2008).
17. Lappin G, Garner RC. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4(12), 1499-1506 (2008).
18. Eap CB, Buclin T, Cucchia G. Oral administration of a low dose of midazolam (75 ug) as an in vivo probe for CYP3A activity. Eur. J. Clin. Pharmacol. 60, 237-246 (2004). (Pubitemid 38916442)
19. Wilhelm S, Carter C, Lynch M. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844 (2006). (Pubitemid 44480537)
20. Kumar S, Kinders R, Guterrez MEE. Phase 0 clinical trial of the poly(ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J. Clin. Oncol. 27, 2705-2711 (2009).
21. US Department of Health And Human Services FDA Center for Drug Evaluation and Research (CDER) Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies (2006) www.fda.gov/cder guidance77086fnl.pdf
22. ICH Topic M 3 (R2): Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (2009) www.emea.europa.eu/pdfs/human/ich/ 028695en.pdf) CPMP/ICH/286/95